EMA/190327/2012

European Medicines Agency decision

P/0056/2012

of 26 March 2012

on the acceptance of a modification of an agreed paediatric investigation plan for prucalopride succinate (Resolor), (EMEA-000459-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision
P/0056/2012

of 26 March 2012

on the acceptance of a modification of an agreed paediatric investigation plan for prucalopride succinate (Resolor), (EMEA-000459-PIP01-08-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/210/2010 issued on 29 October 2010,

Having regard to the application submitted by Shire-Movetis NV on 14 December 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 February 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for prucalopride succinate (Resolor), film-coated tablet, oral solution, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Shire-Movetis NV, Shire-Movetis NV, Veedijk 58 (1004),2300 - Turnhout

Belgium.

Done at London, 26 March 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/190327/2012

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000459-PIP01-08-M01

Scope of the application

Active substance(s):

Prucalopride succinate

Invented name:

Resolor

Condition(s):

Treatment of chronic constipation

Treatment of opioid-induced constipation

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Oral solution

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Shire-Movetis NV

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8409
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Shire-Movetis NV submitted to the European Medicines Agency on 14 December 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/210/2010 issued on 29 October 2010.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 January 2012.

Scope of the modification

Some measures and/or timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 10 February 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition:

Treatment of chronic constipation

The waiver applies to:

- The paediatric population from birth to less than 6 months;
- for film-coated tablets and oral solution, for oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

1.2. Condition:

Treatment of opioid-induced constipation

The waiver applies to:

- The paediatric population from birth to less than 2 years of age;
- for film-coated tablets and oral solution, for oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of chronic constipation

2.1.1. Indication(s) targeted by the PIP

Symptomatic treatment of functional constipation in children aged from 6 months to 18 years.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

- Film-coated tablet, 2 mg
- Oral solution 0.4, mg/ml

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Study 1 Development of liquid age appropriate formulation and strength for oral use.
Non-clinical	1	Study 2 Non-clinical study to investigate the toxicity and toxicokinetics of prucalopride in juvenile rats.
Clinical	1	Study 3 Double-blind placebo-controlled trial to evaluate efficacy, safety, tolerability and pharmacokinetics of prucalopride in children with functional constipation from 6 months to less than 18 years of age, with open-label comparator (PEG) controlled extension to evaluate safety and tolerability up to 24 weeks.

2.2. Condition:

Treatment of opioid-induced constipation.

2.2.1. Indication(s) targeted by the PIP

Symptomatic treatment of opioid-induced constipation resulting from chronic opioid use in children aged from 2 to 18 years.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

- Film-coated tablet, 2 mg
- Oral solution 0.4, mg/ml

2.2.4. Studies

Area	Number of studies	Description
Quality	1	Study 1 Same study as for treatment of chronic constipation.
Non-clinical	1	Study 2

		Same study as for treatment of chronic constipation.
Clinical	1	Study 4 Open-label trial to evaluate the efficacy, safety and tolerability of prucalopride in children from 2 years to less than18 years of age with opioid-induced constipation.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes.
Date of completion of the paediatric investigation plan:	By December 2014.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic constipation

   Authorised indications:

Resolor is indicated for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief.

EU Number	Invented name	Strength	Pharmaceutical form	Route of administration	Packaging	Content (concentration)	Package size
EU/1/09/581/001	Resolor	1 mg	Film-coated tablets	Oral use	blister (alu/alu)		28 x 1 tablet
EU/1/09/581/002	Resolor	2 mg	Film-coated tablets	Oral use	blister (alu/alu)		28 x 1 tablet
EU/1/09/581/003	Resolor	1 mg	Film-coated tablets	Oral use	blister (alu/alu)		7 x 1 tablet
EU/1/09/581/004	Resolor	2 mg	Film-coated tablets	Oral use	blister (alu/alu)		7 x 1 tablet
EU/1/09/581/005	Resolor	1 mg	Film-coated tablets	Oral use	blister (alu/alu)		14 x 1 tablet
EU/1/09/581/006	Resolor	2 mg	Film-coated tablets	Oral use	blister (alu/alu)		14 x 1 tablet
EU/1/09/581/007	Resolor	1 mg	Film-coated tablets	Oral use	blister (alu/alu)		84 x 1 tablet
EU/1/09/581/008	Resolor	2 mg	Film-coated tablets	Oral use	blister (alu/alu)		84 x 1 tablet